Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community

Journal of General Internal Medicine

Volumn 19, Issue 6, 2004, Pages 676-683

  Rochon, Paula A ^a,b,c,d   Sykora, Kathy ^d   Bronskill, Susan E ^c,d   Mamdani, Muhammad ^c,d   Anderson, Geoffrey M ^c,d   Gurwitz, Jerry H ^f   Gill, Sudeep ^a,b   Tu, Jack V ^c,d,e   Laupacis, Andreas ^d,e  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Heart failure; Low dose; Older adults

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; FOSINOPRIL; LISINOPRIL; PERINDOPRIL ERBUMINE; QUINAPRIL; RAMIPRIL; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMMUNITY CARE; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; ODDS RATIO; ONTARIO; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 3042524727     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2004.30328.x     Document Type: Article

References (31)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); 2001. American College of Cardiology Website. Available at: http://www.acc.org/clinical/guidelines/failure/ hf_index.htm. Accessed November 24, 2003.
2. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 1995;26:1376-98.
3. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
4. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-34.
5. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988;259:539-44.
6. Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of heart failure. Am J Cardiol. 1999;83(2A):1A-38A.
7. Packer M. Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-coverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-8.
8. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol. 2000;36:2090-5.
9. Network Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 1998;19:481-9.
10. Clement DL, De Buyzere M, Tomas M, Vanavermaete G, on behalf of the CHIPS investigators. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS). Acta Cardiol. 1999;55:1-7.
11. Krumholz HM, Wang Y, Parent EM, Mocalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med. 1997;157:2242-7.
12. Forman DE, Chander RB, Lapane KL, Shah P, Stoukides J. Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure. J Am Geriatr Soc. 1998;46:1550-4.
13. Chin MH, Wang JC, Zhang JZ, Lang RM. Utilization and dosing of angiotensin-converting enyme inhibitors for heart failure: effect of physician specialty and patient characteristics. J Gen Intern Med. 1997;12:563-6.
14. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359-67.
15. Rochon PA, Anderson GM, Tu JV, et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc. 1999;47:954-9.
16. Rochon PA, Anderson GM, Tu JV, et al. Use of beta-blocker therapy in the elderly following acute myocardial infarction. Can Med Assoc J. 1999;161:1403-8.
17. Naylor CD, Slaughter P. Cardiovascular Health and Services in Ontario. Toronto, Ontario: Institute for Clinical Evaluative Sciences (ICES): 1999.
18. Tu JV, Pashos CL, Naylor CD, et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med. 1997;336:1500-5.
19. Tu J, Hannan EL, Anderson GM, et al. The fall and rise of carotid endarterectomy in the United States and Canada. N Engl J Med. 1998;339:1441-7.
20. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet. 2000;356:639-44.
21. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002;40:675-85.
22. Barron HV, Viskin S, Lundstrom RJ, et al. Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. Arch Intern Med. 1998;158:449-53.
23. Konstam M, Dracup K, Baker D. Heart failure: evaluation and care of patients with left-ventricular systolic cysfunction. Rockville, Md: Agency for Health Care Policy and Research. Public Health Service, U.S. Department of Health and Human Services; 1994.
24. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialities. 33rd ed. Ottawa, Ontario: Canadian Pharmacists Association; 1998.
25. Rochon PA, Fortin PR, Dear KBG, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis: deficiencies and solutions. Arch Intern Med. 1993;153:243-8.
26. Charlson ME, Pompei PA, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
28. Hosmer DW, Lemeshow S. Applied Survival Analysis. New York, NY: John Wiley and Sons; 1999.
29. Argesti A. Categorical Data Analysis. New York, NY: John Wiley and Sons; 1990.
30. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8S):757-63.
31. Uretsky BF, Shaver JA, Liang C et al. Modulation of hemodynamic effects with a converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J. 1988;116:480-8.